High Content Screening

#Academic #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Flow Cytometry #High Content Screening #High throughput screening #Immunology #Lead discovery #Pharmacology #RNA #Screening #Stem cells #Therapeutics #Toxicology

Advanced Therapeutic Antibody Discovery with Multiplexed Screening

Advanced Therapeutic Antibody Discovery with Multiplexed Screening Sponsored by Sartorius Antibody-based therapeutics are the fastest growing and most successful therapeutic modality for treating diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. It is predicted that by the year 2020 there will be 70 therapeutic antibodies on the… Read More

#Archive

#Drug discovery #Drug targets #High Content Screening #Immunology #Oncology #Target validation

Gaining Insights Into Disease Biology for Target Identification and Validation

Gaining Insights Into Disease Biology for Target Identification and Validation Sponsored by Agilent Dysfunctional energy metabolism is associated with many different diseases. As such, metabolic modulation is a promising avenue for novel targets in cancer, immunology, and neurological disease. Learn how live-cell metabolic measurements generate critical information about pathways and… Read More

#Archive

#Drug development #High Content Screening #Immunology #Therapeutics

Spotlight on Abzena’s Developability Platform

Spotlight on Abzena’s Developability Platform during Antibody Engineering & Therapeutics 2019. New service reduces the risk, expenditure and time required for the later stages of antibody development Abzena is showcasing its new Developability Service, enabling biotechnology and pharmaceutical companies to improve lead selection and… Read More

#News

#Academic #Analysis #Assay development optimisation & technology #Business #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Immunology #Lead discovery #Microfluidics #Pharmokinetics #Screening #Therapeutics

Carterra closes financing round for LSA platform

Carterra closes financing round for continued growth of the LSA platform for next generation antibody dscovery. Carterra has closed a $6M round of financing led by Ballast Point Ventures with participation from current investor, Telegraph Hill Partners. The additional funding will support the continued adoption… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Genetics / genomes #High Content Screening #Immunology / Virology & Vaccines #RNA

The most discussed and shared scientific research of 2019

Climate crisis, artificial intelligence, and vaccines top the list of 2019’s most discussed research. From the increasing use of artificial intelligence to the climate emergency facing us all, many of this year’s most polarizing issues feature in the Altmetric Top 100, released today. The… Read More

#News

#Business #Drug development #Drug discovery #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Preclinical #Regulatory #Stem cells

Cancer Research UK collaborate to develop head and neck cancer vaccine

This a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC) HNSCC is the UK’s eighth most common cancer, but treatment options are limited and around 4,000 of those affected in the… Read More

#Cancer Research #News

#Academic #Business #Cell therapy #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Drug target for aggressive breast cancer found

A team of British and American scientists has discovered a way to slow the growth of breast cancer stem cells in the lab. The study led by Dr Bruno Simões and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously… Read More

#Cancer Research #News

#Academic #Business #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK government advises drug companies to stockpile in case of Brexit disruption

Image: Joshua Coleman According to the Department of Health and Social Care (DHSC), pharmaceutical companies should stockpile six weeks’ worth of goods “to help ensure the continuity of supply of medical goods into and out of the UK”. In a letter to the industry Steve Oldfield, Chief Commercial Officer,… Read More

#Covid-19 #News

#Academic #Biologics / Biotechnology #Business #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Just-Evotec Biologics to make monoclonal antibody products for COVID-19

Image: Ani Kolleshi The US Department of Defence (DOD) has awarded Evotec’s Seattle-based subsidiary, Just-Evotec Biologics a contract worth $18.2 million to develop monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19 Under the contract, Just–Evotec Biologics will design a manufacturing process for the production of Current Good… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cell therapy #Cellular assays #Chemical engineering #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Oncology #RNA #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Merging two immunotherapies may be more effective treatment against some cancers

Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of… Read More

#Cancer Research #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Precision medicine #Preclinical #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

British Patient Capital invests in life-changing biotech companies

British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Clinical specialities #Clinical trials #Drug discovery #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Protein chemistry / Proteomics #Therapeutics

PerkinElmer launches virtual open access Covid-19 Data Dashboards to accelerate research

The company has launched two online, free-to-access Covid-19 Data Dashboards to aid the global scientific community accelerate the discovery of antivirals and vaccines. The informatics tools are set to help scientists access, aggregate and analyse drug compound and clinical trial data and are powered by PerkinElmer’s data analytics… Read More

#Covid-19 #News

#Academic #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Top Ten UK organisations for animal research announced

Understanding Animal Research (UAR), which promotes openness about animal research, has released a list of the ten organisations in Great Britain that carry out the highest number of animal procedures in medical, veterinary and scientific research. These statistics are freely available on the organisations’ websites as part of… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #Therapeutics #Translational #Translational chemistry

Quantro Therapeutics offers breakthrough oncology drug discovery platform

21 July 2020 Image: Anshu A Thanks to seed financing from Boehringer Ingelheim Venture Fund (BIVF) and Evotec, Quantro Therapeutics will generate a drug discovery pipeline, aiming to transform the precision and scope of cell-based compound screens. With the introduction of ‘Transcriptional Fingerprinting’ to drug discovery, Quantro intends… Read More

#News

#Academic #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK pharma body says COVID-19 vaccine may still be many months away

Image: Dimitri Houtteman A COVID-19 vaccine being developed by Oxford University and AstraZeneca has generated an immune response in a study of roughly 1,000 patients, according to interim results. The Association of the British Pharmaceutical Industry (ABPI) has responded to the results of the Oxford – AstraZeneca vaccine… Read More

#Covid-19 #News

#Academic #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Protein chemistry / Proteomics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Sphere Fluidics and Heriot-Watt University develop droplet generator instrumentation

20 July 2020 Image: Toa Heftiba Sphere Fluidics and Heriot-Watt University have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency. The grant will facilitate the development of novel droplet generator instrumentation, which will be used to expand Sphere Fluidics’ portfolio of… Read More

#News